Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,252.20
Bid: 1,253.20
Ask: 1,253.60
Change: 0.00 (0.00%)
Spread: 0.40 (0.03%)
Open: 1,248.00
High: 1,255.60
Low: 1,221.60
Yest. Close: 1,243.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Amicus shares fall after Fabry drug fails late-stage study

Dec 20 (Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study. The company's shares were down 43 percent at $3.28 in early trading on Thursday on the

20 Dec 12 15:47

Thursday newspaper round-up: BAE Systems, Mark Carney, Japan...

The continued haggling with Saudi Arabia over the price of 48 Eurofighter Typhoon jets could hit full-year profits at BAE Systems. The British defence contractor said that negotiations with the Royal Saudi Air Force about the price of the aircraft may not be concluded before its results announcement

20 Dec 12 06:51

Amicus's shares tank after Fabry disease drug fails trial

Dec 19 (Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended trade on Wednesday. The company is developing migalastat HCl in partnership with British drugmaker

19 Dec 12 22:48

UPDATE 1-Uncertainty surrounds potential for Novo's Tresiba

(Adds details, analyst quote) By Shida Chayesteh COPENHAGEN, Dec 19 (Reuters) - As Danish group Novo Nordisk awaits final approvals for its new long-acting diabetes drug Tresiba, a Reuters poll found a wide range of forecasts for sales of a drug meant to challenge its biggest rivals. Tresiba's annu

19 Dec 12 18:17

Glaxo reaches $150 mln settlement in nasal spray litigation

Dec 19 (Reuters) - British drugmaker GlaxoSmithKline Plc has reached a $150 million preliminary settlement with U.S. drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents. The settlement was r

19 Dec 12 17:11

UPDATE 2-Merck KGaA, Oncothyreon hit as cancer vaccine fails

* Stimuvax fails to improve survival of lung cancer patients * Effects seen in some patients but analysts sceptical * News is setback for therapeutic cancer vaccine field * Merck falls 3.3 pct, Oncothyreon down 70 pct in premarket (Adds analyst comments, latest shares) By Maria Sheahan and Ben Hir

19 Dec 12 12:17

UPDATE 2-Merck KGaA, Oncothyreon hit as cancer vaccine fails

* Stimuvax fails to improve survival of lung cancer patients * Effects seen in some patients but analysts sceptical * News is setback for therapeutic cancer vaccine field * Merck falls 3.3 pct, Oncothyreon down 70 pct in premarket (Adds analyst comments, latest shares) By Maria Sheahan and Ben Hir

19 Dec 12 12:17

UPDATE 2-Merck KGaA, Oncothyreon hit as cancer vaccine fails

* Stimuvax fails to improve survival of lung cancer patients * Effects seen in some patients but analysts sceptical * News is setback for therapeutic cancer vaccine field * Merck falls 3.3 pct, Oncothyreon down 70 pct in premarket (Adds analyst comments, latest shares) By Maria Sheahan and Ben Hir

19 Dec 12 12:17

UPDATE 1-Merck KGaA cancer drug Stimuvax fails late-stage trial

* Stimuvax fails to improve survival of lung cancer patients * Merck: saw "notable treatment effects" on some patients * Merck says to analyse more data in coming weeks * Merck shares fall 3.5 percent (Adds further details, background) FRANKFURT, Dec 19 (Reuters) - German drugmaker Merck KGaA's c

19 Dec 12 08:32

UPDATE 1-Merck KGaA cancer drug Stimuvax fails late-stage trial

* Stimuvax fails to improve survival of lung cancer patients * Merck: saw "notable treatment effects" on some patients * Merck says to analyse more data in coming weeks * Merck shares fall 3.5 percent (Adds further details, background) FRANKFURT, Dec 19 (Reuters) - German drugmaker Merck KGaA's c

19 Dec 12 08:32

UPDATE 1-Merck KGaA cancer drug Stimuvax fails late-stage trial

* Stimuvax fails to improve survival of lung cancer patients * Merck: saw "notable treatment effects" on some patients * Merck says to analyse more data in coming weeks * Merck shares fall 3.5 percent (Adds further details, background) FRANKFURT, Dec 19 (Reuters) - German drugmaker Merck KGaA's c

19 Dec 12 08:32

Number of new drugs picks up in Europe and U.S.

* EU agency sees more new drug applications in 2013 * U.S. new drug approvals running at eight-year high * Encouraging signals for industry as patent losses peak By Ben Hirschler LONDON, Dec 18 (Reuters) - The number of new medicines approved or pending approval is on the rise on both sides of the A

18 Dec 12 17:20

GlaxoSmithKline submits regulatory application for UMEC/VI

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD). UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidi

18 Dec 12 12:05

TEXT-S&P report: Big Pharma won't fall off a patent cliff

(The following statement was released by the rating agency) Dec 18 - Most global pharmaceutical firms will survive unscathed the spike in expiries of patented drugs this year known as the "patent cliff", says Standard & Poor's Ratings Services today in the report card: "Why Global Pharmaceutical Fir

18 Dec 12 10:27

Wednesday broker round-up UPDATE

AMEC: Credit Suisse reduces target price from 1300p to 1250p reiterating an outperform rating. Anglo American: Barclays upgrades to equal-weight with a target price of 1970p. Ashtead Group: Barclays raises target price from 352p to 434p and reiterates an overweight rating. ASOS: HSBC raises targe

12 Dec 12 07:25

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.